Clinical trials: Migraine Headache
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label phase.
- Trial name
- NCT00168428
- Testing
- Botulinum Toxin Type A
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 705 people
- Sponsor
- Allergan
Migraine Without Aura, Migraine With Aura
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
Primary objective: To investigate the efficacy and tolerability of two doses of tonabersat compared to placebo in the prophylaxis of migraine headache and to evaluate the longer term tolerability of tonabersat in an open label…
- Trial name
- TEMPUS (NCT00534560)
- Testing
- Tonabersat
- Volunteers
- 542 people
- Sponsor
- Minster Research Ltd
Migraine
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PHASES (NCT07310290)
- Where
- 3 sites in United States
- Volunteers
- 189 people
- Sponsor
- AbbVie
Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
- Trial name
- NCT03934086
- Testing
- rimegepant
- Sponsor
- Pfizer
Migraine, Acute Treatment of Migraine
Nerivio Long-term Usage in Patients With Migraine
This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
- Trial name
- NCT06738056
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Theranica
Migraine, With or Without Aura
Open Label Safety Study in Acute Treatment of Migraine
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
- Trial name
- NCT03266588
- Testing
- Rimegepant
- Where
- 98 sites in United States
- Volunteers
- 3,019 people
- Sponsor
- Pfizer
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine, Migraine With Aura
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment…
- Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT06051604
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- CoolTech LLC
Migraine
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT04804033
- Testing
- BHV-3500 (zavegepant)
- Where
- 116 sites in United States
- Volunteers
- 1,753 people
- Sponsor
- Pfizer
Migraine
Bioequivalence of Two Tablet Forms of MK0974 (0974-045)
This study will evaluate the bioequivalence of two solid dose formulations of MK0974.
- Trial name
- NCT00965887
- Testing
- MK0974 Ethanolate formulation, Comparator: MK0974 Hydrate formulation
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Menstrual Migraine (MM) Headaches
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine
Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the early stage (International…
- Trial name
- NCT00904098
- Testing
- Frovatriptan, Usual Care
- Where
- 21 sites in United States
- Volunteers
- 192 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Migraine, Headache
Improvement of Migraine Severity and Frequency With Migraineguard ™
Numerous treatments have been recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled trial was to assess the efficacy of MIGRAINEGUARD ™ supplement by Herbacure Natural…
- Trial name
- NCT04759040
- Testing
- Migraineguard
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Herbacure Natural
Migraine, Vascular Headaches
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the prevention of migraine attacks in children (12 to 17 years of age).
- Trial name
- NCT00210535
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine
A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients
This trial assesses the safety of TEV-48125 when subcutaneously self-administered in Japanese migraine patients using an autoinjector (AI) at home.
- Trial name
- NCT04355117
- Testing
- Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Right to Left Shunt, Patent Foramen Ovale
Right to Left Cardiac Shunt Detection
The purpose of this study is to evaluate the sensitivity and specificity of the Cardiox Flow Detection System (FDS) in identifying an intracardiac right-to-left shunt (RLS) compared to the results of transesophageal…
- Conditions
- Right to Left Shunt, Patent Foramen Ovale, Atrial Septal Defect
- Trial name
- PFO Detection (NCT01773252)
- Testing
- Flow Detection System
- Where
- 8 sites in United States
- Volunteers
- 141 people
- Sponsor
- Cardiox Corporation
Vascular Headaches, Migraine
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate (an epilepsy medication) compared with placebo in the prevention of migraine.
- Trial name
- NCT00253175
- Testing
- topiramate
- Volunteers
- 211 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine Without Aura, Migraine With Aura
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Evaluation of headache response at 2 hours for active treated attacks for increasing dose.
- Trial name
- NCT01859481
- Testing
- Eletriptan HBr 40 mg, Eletriptan HBr 80 mg
- Where
- 148 sites in Belgium, Czechia and 12 more
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Patent Foramen Ovale
PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)
The primary objective of this study is to demonstrate the safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Trial name
- NCT00335296
- Testing
- PFx catheter
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Cierra
Menstrually Associated Migraine
A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine
The primary objective of this study was to determine whether frovatriptan was effective in the prevention of menstrually associated migraine (MAM) headaches when compared to placebo.
- Trial name
- NCT00644033
- Testing
- Frovatriptan
- Where
- United States
- Volunteers
- 579 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acute Migraine
Migraine Treatment With Nerivio Migra Neurostimulation Device
This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
- Trial name
- NCT03076515
- Testing
- Nerivio Migra neurostimulation
- Where
- 8 sites in United States, Israel
- Volunteers
- 120 people
- Sponsor
- Theranica